Inbec Tablets
Composition: Abacavir, Dolutegravir & Lamivudine Tablets
International Trade Name: Triumeq®
Inbec is a high-quality fixed-dose combination tablet of Abacavir, Dolutegravir, and Lamivudine, a bioequivalent formulation of the internationally recognized antiretroviral medicine marketed under the brand name Triumeq®. Manufactured in WHO-GMP certified pharmaceutical facilities, Inbec Tablets are supplied by trusted pharmaceutical exporters from India to support global HIV/AIDS treatment programs, offering a convenient once-daily regimen that improves adherence and long-term treatment outcomes.
This combination brings together three potent antiretroviral agents: Abacavir (a nucleoside reverse transcriptase inhibitor), Dolutegravir (an integrase strand transfer inhibitor), and Lamivudine (a nucleoside reverse transcriptase inhibitor). Together, they act at different stages of the HIV replication cycle, providing rapid viral suppression and a high barrier to resistance. Inbec Tablets are primarily indicated for the treatment of HIV-1 infection in adults and adolescents, in accordance with national and international HIV treatment guidelines.
Abacavir Dolutegravir Lamivudine tablets, Inbec tablet, Triumeq generic, HIV single-tablet regimen, fixed-dose combination ART, integrase inhibitor–based HIV therapy, pharmaceutical exporter India, and antiretroviral manufacturer India.
Inbec Tablets are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent potency, safety, and therapeutic efficacy. The tablets are supplied in secure, export-grade, tamper-proof packaging with complete regulatory and quality documentation, making them suitable for government HIV programs, hospitals, ART centers, global health initiatives, NGOs, and international pharmaceutical distributors worldwide.